Drug Approval | April 24, 2023
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The interaction with key Government Officials and industry leaders led to a joint exploration of possible collaboration and investments in the Healthcare ecosystem between the two countries
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
SÜDPACK is setting standards in terms of both performance and sustainability
Gafchromic films support patient care in oncology
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
With the combination of oral solid, inhalation, dermatology, high potent and oral contraceptive products, this is an important facility of the company
The observations are procedural in nature
Subscribe To Our Newsletter & Stay Updated
